natgillin/translations-raw huggingface dataset:
The humanized anti-a2 integrin antibody according to any one of claims 1-16 or the composition of claim 28 for use in a method for the treatment of an a2β1 integrin-associated disorder selected from inflammatory disease, autoimmune disease, a disease associated with abnormal or higher than normal angiogenesis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, reactions to transplant, optical neuritis, spinal cord trauma, rheumatoid arthritis, systemic lupus erythematosus (SLE), diabetes mellitus, multiple sclerosis, Reynaud's syndrome, experimental autoimmune encephalomyelitis, Sjorgen's syndrome, scleroderma, juvenile onset diabetes, diabetic retinopathy, age related macular degeneration, cardiovascular disease, psoriasis, cancer as well as infections that induce an inflammatory response. 
Humanizirano anti-a2 integrin protutijelo prema bilo kojem od zahtjeva 1-16 ili oblik prema zahtjevu 28 za uporabu u postupku liječenja poremećaja povezanog s a2β1 integrinom, izabranog između inflamatorne bolesti, autoimune bolesti, bolesti povezane s abnormalnom ili povećanom angiogenezom, inflamatorne bolesti crijeva, Crohnove bolesti, ulceroznog kolitisa, reakcije na transplantat, optičkog neuritisa, traume leđne moždine, reumatoidnog artritisa, sistemskog eritematoznog lupusa (SLE), šećerne bolesti, multiple skleroze, Reynaudovog sindroma, eksperimentalnog autoimunog encefalomijelitisa, Sjorgenovog sindroma, skleroderme, juvenilnog dijabetesa, dijabetičke retinopatije, makularne degeneracije povezane sa starenjem, kardiovaskularne bolesti, psorijaze, raka kao i infekcija koje induciraju inflamatorni odgovor.
Use of the humanized anti-a2 integrin antibody according to any one of claims 1-16 for the preparation of a medicament for the treatment of an a2β1 integrin-associated disorder selected from inflammatory disease, autoimmune disease, a disease associated with abnormal or higher than normal angiogenesis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, reactions to transplant, optical neuritis, spinal cord trauma, rheumatoid arthritis, systemic lupus erythematosus (SLE), diabetes mellitus, multiple sclerosis, Reynaud's syndrome, experimental autoimmune encephalomyelitis, Sjorgen's syndrome, scleroderma, juvenile onset diabetes, diabetic retinopathy, age related macular degeneration, cardiovascular disease, psoriasis, cancer as well as infections that induce an inflammatory response. 
Uporaba humaniziranog anti-a2 integrin protutijela prema bilo kojem od zahtjeva 1-16 za pripremu lijeka za liječenje poremećaja povezanog s a2β1 integrinom, izabranog između inflamatorne bolesti, autoimune bolesti, bolesti povezane s abnormalnom ili povećanom angiogenezom, inflamatorne bolesti crijeva, Crohnove bolesti, ulceroznog kolitisa, reakcije na transplantat, optičkog neuritisa, traume leđne moždine, reumatoidnog artritisa, sistemskog eritematoznog lupusa (SLE), šećerne bolesti, multiple skleroze, Reynaudovog sindroma, eksperimentalnog autoimunog encefalomijelitisa, Sjorgenovog sindroma, skleroderme, juvenilnog dijabetesa, dijabetičke retinopatije, makularne degeneracije povezane sa starenjem, kardiovaskularne bolesti, psorijaze, raka kao i infekcija koje induciraju inflamatorni odgovor.
The use according to claim 33, wherein the anti-a2 integrin antibody comprises a heavy chain comprising SEQ ID NO: 174 or SEQ ID NO:176 and a light chain comprising SEQ ID NO: 178. 
Uporaba prema zahtjevu 33, gdje anti-a2 integrin protutijelo ima teški lanac koji obuhvaća SEQ ID NO: 174 ili SEQ ID NO:176 i laki lanac koji obuhvaća SEQ ID NO: 178.
The individually pocketed coil spring of claim 3, wherein the second piece of fabric is secured to the first piece of fabric along a few transverse connection lines extending parallel to the longitudinal direction of the coil spring, said connecting lines preferably consisting of a surface joint, such an adhesive, a weld or the like. 
Pojedinačno ušivena spiralna opruga (2) iz Zahtjeva 3, pri čemu je drugi dio tkanine pričvršćen za prvi dio tkanine duž nekoliko transverzalnih poveznica (33) koje se pružaju paralelno longitudinalnom smjeru spiralne opruge (4), navedene poveznice po mogućnosti sadrže površinsko vezivo, poput ljepila, zavarivanja ili sličnog.
The individually pocketed coil spring (2) according to any one of the preceding claims, wherein it further comprises a second cushioning pad located below said lower end (42) of said coil spring (4), said second cushioning pad being arranged in a third compartment, said third compartment being separated from said first and second compartments (21, 22). 
Pojedinačno ušivena spiralna opruga (2) iz bilo kojeg od prethodnih Zahtjeva, pri čemu nadalje sadrži drugi amortizirajući podložak smješten ispod navedenog donjeg kraja (42) navedene spiralne opruge (4), navedeni drugi amortizirajući podložak smješten je u treći odjeljak, navedeni treći odjeljak odvojen je od navedenih prvog i drugog odjeljka (21, 22).
A pocket spring mattress (1) for use in a bedding or seating product, comprising a plurality of parallel strings (3) of individually pocketed coil spring (2), wherein at least one, and preferably essentially all, of said individually pocketed coil springs is an individually pocketed coil spring in accordance with any one of claims 1-11. 
Madrac s ušivenim oprugama (1) za upotrebu u proizvodima za spavanje ili sjedenje, koji sadrži više paralelnih nizova (3) pojedinačno ušivenih spiralnih opruga (2), pri čemu je barem jedna, a po mogućnosti zapravo sve pojedinačno ušivene spiralne opruge sukladna bilo kojem od Zahtjeva 1-11.
The pocket spring mattress of claim 13 or 14, wherein each of said strings is formed by a first piece of fabric forming said pockets, and a second piece of fabric forming said second compartments, wherein said second piece of fabric is connected to said first piece of fabric along said spaced transverse connecting lines. 
Madrac s ušivenim oprugama (1) iz Zahtjeva 13 ili 14, pri čemu je svaki od navedenih nizova (3) formiran prvim dijelom tkanine koji formira navedene džepove, te drugim dijelom tkanine koji formira navedene druge odjeljke (22), pri čemu je navedeni drugi dio tkanine povezan s navedenim prvim dijelom tkanine duž navedenih razmaknutih transverzalnih poveznica (33).
two hinge bodies (11, 12) for attaching respectively to a fixed frame (13) and to a mobile frame of the door or window(14), 
dva tijela šarke (11, 12) za pričvršćivanje na fiksni okvir (13) odnosno na pokretni okvir za vrata i prozor (14),
The hinge according to claim 3, characterised in that it comprises second means (18) for adjusting the mutual positions of said two hinge bodies 11 and 12 in a direction substantially orthogonal to the plane of the mobile frame to which the hinge is attached, said second means (18) being independent of said crosswise adjustment means (17). 
Šarka u skladu s patentnim zahtjevom 3, naznačena time, da ima drugo sredstvo (18) za podešavanje uzajamnog položaja dvaju navedenih tijela šarke 11 i 12 u smjeru koji je u biti ortogonalan prema ravnini mobilnog okvira na koji je šarka pričvršćena, pri čemu je drugo sredstvo (18) neovisno od navedenog sredstva za poprečno podešavanje (17).
The hinge according to claim 6, characterised in that a further semicircular groove (35a) is formed on said sleeve (29), symmetrically located with respect to said semicircular groove (35) in relation to a vertical plane passing through the sleeve axis, 
Šarka u skladu s patentnim zahtjevom 6, naznačena time, da se na navedenoj navlaci (29) dodatno formira polukružni utor (35a), simetrično postavljen u odnosu na navedeni polukružni utor (35) u odnosu na vertikalnu ravninu koja prolazi kroz os navlake.
An isolated nucleic acid, characterized in that it is chosen from the following nucleic acids: 
Izolirana nukleinska kiselina, naznačena time da je odabrana od sljedećih nukleinskih kiselina:
a nucleic acid, DNA or RNA, coding for an antibody, or one of its antigen binding fragments or "derivatives, as claimed in one of claims 1 and 2; 
nukleinska kiselina, DNA ili RNA koja kodira antitijelo ili jedan od njegovih divaletnih fragmenata koji se veže na c-Met kao što je prijavljeno u patentnim zahtjevima 1 i 2,
the complementary nucleic acids of the nucleic acids as defined in a), b) and c). 
nukleinske kiseline komplementarne nukleinskim kiselinama definiranih u a), b) i c).
A composition comprising as an active principle a compound consisting of an antibody, or one of its antigen binding fragments or derivatives, as claimed in one of claims 1, 2, and 4-8, or obtained by the method of claim 12, or produced by hybridoma according to claim 3. 
Pripravak koji kao aktivni sastojak sadrži spoj koji se sastoji od antitijela ili jednog od njegovih divalentnih fragmenata koji se vežu na c-Met kao što je prijavljeno u jednom od patentnih zahtjeva 1, 2 te 4 - 8 ili je dobiven metodom iz patentnog zahtjeva 12, ili je dobiven pomoću hibridoma prema patentnom zahtjevu 3.
The composition of claim 14, characterized in that it further comprises one agent as a combination product for simultaneous, separate or sequential use, and wherein said agent is an anti-tumoral antibody. 
Pripravak iz patentnog zahtjeva 14, naznačen time da dalje sadrži jedno sredstvo kao kombinacijski produkt za istodobnu, odvojenu ili uzastopnu upotrebu, pri čemu rečeno sredstvo jest antitumorsko antitijelo.
The composition of claim 14 or 15, characterized in that it further comprises at least one agent as a combination product for simultaneous, separate or sequential use, wherein said agent is a cytotoxic/cytostatic agent. 
Pripravak iz patentnog zahtjeva 14 ili 15, naznačen time da dalje sadrži najmanje jedno sredstvo kao kombinacijski produkt za istodobnu, odvojenu ili uzastopnu upotrebu, pri čemu rečeno sredstvo jest citotoksično/citostatko sredstvo.
R5a is selected from hydrogen, halo, and alkoxy; 
a je odabran od vodika, halo i alkoksi;
R5b is selected from hydrogen, halo, and alkyl; 
b je odabran od vodika, halo i alkila;
RC is selected from phenyl, heteroaryl, and saturated heterocyclyl, wherein the group represented by RC is optionally substituted with 1 to 2 substituents independently selected from halo, -CN, alkyl, alkoxy, haloalkoxy, haloalkyl, and carbamyl; and R' is selected from hydrogen, alkyl, and alkoxyalkyl. 
Rc je odabran od fenila, heteroarila i zasićenog heterociklila, dok je skupina predstavljena s Rc po želji supstituirana s 1 do 2 supstituenta neovisno odabrana od sljedećih: halo, -CN, alkil, alkoksi, haloalkoksi, haloalkil i karbamil; i R' je odabran od vodika, alkila i alkoksialkila.
A pharmaceutical composition comprising: i) the compound of any one of Claims 1-9 or a pharmaceutically acceptable salt thereof; and ii) a pharmaceutically acceptable adjuvant, carrier or vehicle. 
Farmaceutski sastav, naznačen time, da obuhvaća: i) spoj prema bilo kojem od zahtjeva 1 do 9 ili njegovu farmaceutski prihvatljivu sol, i ii) farmaceutski prihvatljiv/o pomoćno sredstvo, nosač ili pokretač.
A compound according to any one of Claims 1-9 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to Claim 10, for use in treating a disease or condition selected from cancer and other proliferative disorders, inflammatory diseases, sepsis, autoimmune disease, and viral infections. 
Spoj prema bilo kojem od zahtjeva 1 do 9, ili njegova farmaceutski prihvatljiva sol, ili farmaceutski sastav prema zahtjevu 10, naznačen/a time, da se upotrebljava u liječenju bolesti ili stanja odabranog od raka i ostalih proliferativnih poremećaja, upalnih bolesti, sepse, autoimune bolesti i virusnih infekcija.
The compound or composition for use according to Claim 11, wherein the disorder is cancer. 
Spoj ili sastav za uporabu prema zahtjevu 11, naznačen time, da poremećaj je rak.
The compound or composition for use according to Claim 11, wherein the disorder is sepsis, rheumatoid arthritis, irritable bowel syndrome or psoriasis. 
Spoj ili sastav za uporabu prema zahtjevu 11, naznačen time, da poremećaj je sepsa, reumatoidni artritis, sindrom nadraženih crijeva ili psorijaza.
A compound as claimed in any one of the preceding claims, in which each of R3, R4, R5 and R6 is independently selected from the group consisting of hydrogen, ORA, halogen, cyano, C1-4alkyl, haloC1-4alkyl, dihaloC1-4alkyl, and trihaloC1-4alkyl, preferablyhydrogen, OH, halogen, cyano, methyl, and trifluoromethyl. 
Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time da svaki od R3, R4, R5 i R6 je neovisno odabran iz skupine koju čine vodik, ORA, halogen, cijano, C1-4alkil, haloC1-4alkil, dihaloC1-4alkil, i trihaloC1-4alkil, poželjno vodik, OH, halogen, cijano, metil, te trifluorometil.
A compound as claimed in claim 7, in which R1 is selected from the group consisting of ORA, N(RB)2, -C(O)C1-4alkyl, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, phenyl, and 5-6 membered heterocyclyl, wherein said phenyl or heterocyclyl group can either be unsubstituted or substituted by 1 to 3 substituents selected from halogen, cyano, C1-4alkyl, -C(O)C1-4alkyl, and ORA; 
Spoj prema zahtjevu 7, naznačen time da R1 je odabran iz skupine koja sadrži ORA, N(RB)2, -C(O)C1-4alkil, C1-4alkil, C2-4alkenil, C2-4alkinil, fenil, i 5-6 člani heterociklil, pri čemu navedena fenil ili heterociklil skupina može biti ili nesupstituirana ili supstituirana s 1 do 3 supstituenata odabrana od halogena, cijano, C1-4alkila, -C(O)C1-4alkila, i ORA;
A compound as claimed in claim 11, in which R1 is a 5-membered heterocyclyl group, wherein said heterocyclyl group is substituted with two substituents independently selected from methyl and ethyl; 
Spoj prema zahtjevu 11, naznačen time da R1 je 5-člana heterociklil skupina, pri čemu navedena heterociklil skupina je supstituirana s dva supstituenta neovisno odabrana od metila i etila;
a nucleic acid, DNA or RNA, coding for an antibody, or one of its c-Met binding divalent fragments, as claimed in one of claims 1 and 2; 
nukleinska kiselina, DNA ili RNA koja kodira antitijelo ili jedan od njegovih divaletnih fragmenata koji se veže na c-Met kao što je prijavljeno u patentnim zahtjevima 1 i 2,
A composition comprising as an active principle a compound consisting of an antibody, or one of its c-Met binding activity divalent fragments, as claimed in one of claims 1, 2, and 4-8, or obtained by the method of claim 12, or produced by hybridoma according to claim 3. 
Pripravak koji kao aktivni sastojak sadrži spoj koji se sastoji od antitijela ili jednog od njegovih divalentnih fragmenata koji se vežu na c-Met kao što je prijavljeno u jednom od patentnih zahtjeva 1, 2 te 4 - 8 ili je dobiven metodom iz patentnog zahtjeva 12, ili je dobiven pomoću hibridoma prema patentnom zahtjevu 3.
a sequence consisting of SEQ ID No. 1 
sekvence koja se sastoji od SEQ ID br. 1
The peptide according to any of claims 1 to 3, wherein said peptide is part of a fusion protein, in particular comprising N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii). 
Peptid u skladu s bilo kojim patentnim zahtjevom od 1 ili 3, pri čemu je navedeni peptid dio fuzijske bjelančevine koja se sastoji od N-terminalne aminokiseline HLA-DR invarijantnog lanca vezanog za antigene (Ii).
A nucleic acid, encoding a peptide according to any one of claims 1 to 6, provided, that the peptide is not the full human protein, wherein preferably said nucleic acid is DNA, cDNA, PNA, RNA or a combination thereof, or an expression vector expressing said nucleic acid. 
Nukleinska kiselina, koja kodira peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 4, uz uvjet da peptid nije potpuno humani protein, pri čemu je navedena nukleinska kiselina po mogućnosti DNK, cDNK, PNK, RNK ili kombinacija navedenih, ili ekspresijski vektor koji eksprimira navedenu nukleinsku kiselinu.
A host cell, comprising a nucleic acid or an expression vector according to claim 5, which is an antigen presenting cell. 
Stanica domaćin, sastoji se od nukleinske kiseline ili ekspresijskog vektora u skladu s patentnim zahtjevom 5, koja je stanica koja prezentira antigen.
An activated cytotoxic T lymphocyte (CTL), produced by the method according to Claim 9 or 10, which selectively recognises a peptide according to claim 1 or 2. 
Aktivirani citotoksični T-limfocit (CTL), proizveden metodom u skladu s patentnim zahtjevom 9 ili 10, koji selektivno prepoznaje peptid u skladu sa zahtjevom 1 ili 2.
The peptide, the nucleic acid or an expression vector, the cell, or the activated cytotoxic T lymphocyte for use according to claim 13, wherein said medicament is a vaccine. 
Peptid, nukleinska kiselina ili ekspresijski vektor, stanica, aktivirani citotoksični T-limfocit za upotrebu u skladu s patentnim zahtjevom 13, pri čemu je lijek cjepivo.
The apparatus of Claim 1 wherein said dual functioning biasing member comprises a coiled spring (290) having first and second ends (297, 293) that directly engage said follower and said shuttle respectively. 
Uređaj prema zahtjevu 1, naznačen time, što se spomenuti element za potiskivanje s dvostrukom funkcijom sastoji od namotane opruge (290) koja ima prvi i drugi kraj (297, 293) koji se direktno ukopčava sa spomenutim sljedilom, odnosno čunkom.
The apparatus of Claim 2 wherein said coiled spring first end includes a radially outwardly extending tip (296) that fits within a complementarily shaped recess formed by an opening (266) through a body of said follower. 
Uređaj prema zahtjevu 2, naznačen time, što prvi kraj spomenute namotane opruge uključuje vrh koji se radijalno proteže prema van (296) koji se uklapa u komplementarno oblikovano udubljenje koje formira otvor (266) kroz trup spomenutog sljedila.
as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; 
u obliku svog stereoizomera, enantiomera, tautomera ili njihovih smjesa;
The peptide according to any of claims 1 to 3, wherein said peptide is part of a fusion protein comprising N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii). 
Peptid u skladu s bilo kojim patentnim zahtjevom od 1 ili 3, pri čemu je navedeni peptid dio fuzijske bjelančevine koja se sastoji od N-terminalne aminokiseline HLA-DR invarijantnog lanca vezanog za antigene (Ii).
A nucleic acid, encoding a peptide according to any one of claims 1 to 4, provided that said peptide is not the full human protein, wherein preferably said nucleic acid is DNA, cDNA, PNA, RNA or a combination thereof, or an expression vector expressing said nucleic acid. 
Nukleinska kiselina, koja kodira peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 4, uz uvjet da peptid nije potpuno humani protein, pri čemu je navedena nukleinska kiselina po mogućnosti DNK, cDNK, PNK, RNK ili kombinacija navedenih, ili ekspresijski vektor koji eksprimira navedenu nukleinsku kiselinu.
A host cell, comprising a nucleic acid or an expression vector according to Claim 5, which preferably is an antigen presenting cell, such as, for example, a dendritic cell. 
Stanica domaćin, sastoji se od nukleinske kiseline ili ekspresijskog vektora u skladu s patentnim zahtjevom 5, koja je stanica koja prezentira antigen.
An activated cytotoxic T lymphocyte (CTL), produced by the method according to Claim 9 or 10, which selectively recognises a cell which aberrantly expresses a polypeptide comprising an amino acid sequence given in claim 1 or 2. 
Aktivirani citotoksični T-limfocit (CTL), proizveden metodom u skladu s patentnim zahtjevom 9 ili 10, koji selektivno prepoznaje peptid u skladu sa zahtjevom 1 ili 2.
The peptide, the nucleic acid or an expression vector, the cell, or the activated cytotoxic T lymphocyte for use according to claim 13, wherein said peptides are for use as a vaccine. 
Peptid, nukleinska kiselina ili ekspresijski vektor, stanica, aktivirani citotoksični T-limfocit za upotrebu u skladu s patentnim zahtjevom 13, pri čemu je lijek cjepivo.
The method of claim 1, wherein the reactive polymeric material is a single hydrophilic polymeric material comprising electrophilic reactive groups, wherein the hydrophilic polymeric material is a hydrophilic crosslinker. 
osiguravanja jedne hidrofilne polimerne komponente koja sadrži elektrofilne reaktivne skupine u obliku otopine, pri čemu navedeni jedan reaktivni polimerni materijal je hidrofilno sredstvo za umrežavanje,
A compound of formula 1 as claimed in claim 1 which is: and/or at least one pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1 naznačen time da je: [image] i/ili najmanje jedna njegova farmaceutski prihvatljiva sol.
At least one compound of formula 1 as claimed in any one of claims 1 to 11, and/or at least one pharmaceutically acceptable salt thereof, for use in the treatment of cancer as claimed in claim 13, where the cancer is selected from lung cancer, head and neck cancer, colorectal cancer, pancreatic cancer, colon cancer, breast cancer, ovarian cancer, prostate cancer, stomach cancer, kidney cancer, liver cancer, brain cancer, bone cancer, and leukaemia. 
Najmanje jedan spoj prema bilo kojem od patentnih zahtjeva 1 do 3, i/ili najmanje jedna njegova farmaceutski prihvatljiva sol, naznačen time da je za uporabu za liječenje raka prema zahtjevu 7, pri čemu je rak odabran od raka pluća, raka glave i vrata, kolorektalnog raka, raka gušterače, raka debelog crijeva, raka dojke, raka jajnika, raka prostate, raka želuca, raka bubrega, raka jetre, raka mozga, raka kosti, te leukemije.
The process of claim 1 or 2 further comprising the step of drying the resulting monohydrate under reduced pressure until the compound of the formula (I) is formed. 
Postupak prema zahtjevu 1 ili 2 naznačen time da dodatno sadrži korak sušenja nastalog monohidrata pod sniženim tlakom sve do nastanka spoja s formulom (I).
The process of any of claims 1 to 3 wherein the acid is generated in situ in the reaction mixture after the compound of the formula (I) is formed by adding to the reaction mixture a protic substance and an acid precursor. 
Postupak prema bilo kojem od zahtjeva 1 do 3 naznačen time da se kiselina stvara in situ u reakcijskoj smjesi nakon što je nastao spoj s formulom (I) dodavanjem protične tvari i prekursora kiseline u reakcijsku smjesu.
The process of claim 4 wherein the acid is generated in situ in the reaction mixture after the compound of the formula (I) is formed by adding to the reaction mixture an alcohol and an acylchloride. 
Postupak prema zahtjevu 4 naznačen time da se kiselina stvara in situ u reakcijskoj smjesi nakon što je nastao spoj s formulom (I) dodavanjem alkohola i acilklorida u reakcijsku smjesu.
The process of claim 7 wherein the compound of the formula (III) is used in a solution of a suitable organic solvent and is formed by reacting 4-amino-3-fluorophenol with the compound of the formula (VI) wherein R1 and R2 are independently selected from the group consisting of hydrogen, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n -pentyl, 2-pentyl, 3-pentyl, neopentyl, n -hexyl, 2-hexyl and 3-hexyl, or R1 and R2 are joined and, taken together with the carbon atom to which they are attached, form a 4- to 7- membered cycloalkyl ring. 
Postupak prema zahtjevu 7 naznačen time da se spoj s formulom (III) koristi u otopini prikladnog organskog otapala i nastaje reakcijom 4-amino-3-fluorofenola sa spojem s formulom (VI) [image] pri čemu R1 i R2 su neovisno odabrani iz skupine koja sadrži vodik, metil, etil, n-propil, izo-propil, n-butil, izo-butil, sek-butil, tert-butil, n-pentil, 2-pentil, 3-pentil, neopentil, n-heksil, 2-heksil i 3-heksil, ili i R2 su spojeni, te zajedno s atomom ugljika na koji su vezani, tvore 4- do 7- člani cikloalkilni prsten.
The process of claim 7 or 8 wherein the compound of the formula (II) is used in a solution of a suitable organic solvent which solution is prepared by neutralization the hydrochloric acid salt of the compound of the formula (II) with a base. 
Postupak prema zahtjevu 7 ili 8 naznačen time da se spoj s formulom (II) koristi u otopini prikladnog organskog otapala te se navedena otopini priprema neutralizacijom soli klorovodične kiseline spoja s formulom (II) sa bazom.
The process of claim 10 wherein the protic substance is an alcohol and the acid precursor is an acylchloride. 
Postupak prema zahtjevu 10 naznačen time da je protična tvar alkohol i prekursor kiseline je acilklorid.